T1820000
Trapidil
European Pharmacopoeia (EP) Reference Standard
Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
About This Item
Formula empirica (notazione di Hill):
C10H15N5
Numero CAS:
Peso molecolare:
205.26
Numero MDL:
Codice UNSPSC:
41116107
ID PubChem:
NACRES:
NA.24
Prodotti consigliati
Grado
pharmaceutical primary standard
Famiglia di API
trapidil
Produttore/marchio commerciale
EDQM
applicazioni
pharmaceutical (small molecule)
Formato
neat
Temperatura di conservazione
2-8°C
Stringa SMILE
CCN(CC)c1cc(C)nc2ncnn12
InChI
1S/C10H15N5/c1-4-14(5-2)9-6-8(3)13-10-11-7-12-15(9)10/h6-7H,4-5H2,1-3H3
GSNOZLZNQMLSKJ-UHFFFAOYSA-N
Cerchi prodotti simili? Visita Guida al confronto tra prodotti
Descrizione generale
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Applicazioni
Trapidil EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Azioni biochim/fisiol
Trapidil is an antiplatelet agent that acts in part as a phosphodiesterase inhibitor and as a competitive inhibitor of the platelet-derived growth factor (PDGF) receptor. Trapidil, with its vasodilator and NO releasing effect may have some potential to diminish the tissue injury. Trapidil suppresses platelet-derived growth factor (PDGF)-induced vascular smooth muscle cell (VSMC) proliferation by inhibiting Raf-1/extracellular signal-regulated kinase (ERK) via cAMP/protein kinase A (PKA). In addn. to cAMP/PKA activation, trapidil inhibits RhoA/ROCK activation.
Confezionamento
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Altre note
Sales restrictions may apply.
Avvertenze
Warning
Indicazioni di pericolo
Consigli di prudenza
Classi di pericolo
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
Organi bersaglio
Respiratory system
Codice della classe di stoccaggio
11 - Combustible Solids
Classe di pericolosità dell'acqua (WGK)
WGK 3
Punto d’infiammabilità (°F)
Not applicable
Punto d’infiammabilità (°C)
Not applicable
Scegli una delle versioni più recenti:
Certificati d'analisi (COA)
Lot/Batch Number
Ci dispiace, ma al momento non ci sono COA disponibili online per questo prodotto.
Se ti serve aiuto, non esitare a contattarci Servizio Clienti
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
Russell T Turner et al.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 25(7), 1637-1649 (2010-03-05)
Chronic hyperparathyroidism (HPT) is a common cause of metabolic bone disease. These studies investigated the underlying cellular and molecular mechanisms responsible for the detrimental actions of elevated parathyroid hormone (PTH) on the skeleton. Bone biopsies from hyperparathyroid patients revealed an
Salih Somuncu et al.
Pediatric surgery international, 24(3), 315-318 (2007-12-07)
We aimed to detect the protective effect of trapidil in ischemia-reperfusion (IR) injury due to ovarian torsion and detorsion. Thirty-two pubertal New Zealand albino rabbits were used. Adnexal torsion was created by rotating the left adnexa including the tubal and
W Sziegoleit et al.
International journal of clinical pharmacology and therapeutics, 45(1), 10-15 (2007-01-30)
In this study the effect of locally administered trapidil on human hand veins was examined. 10 healthy male volunteers aged 20 - 30 years were included. The dorsal hand vein compliance technique was used. In a crossover design the influence
John S Douglas
The American journal of cardiology, 100(5A), 10K-16K (2007-09-28)
Despite significant advances in technology and technique, coronary restenosis remains the primary limitation of percutaneous transluminal coronary angioplasty (PTCA). Among patients undergoing PTCA, between 20% and 50% of patients who do not receive a stent and 10%-30% of those who
Jodie M Dodd et al.
The Cochrane database of systematic reviews, (6)(6), CD006780-CD006780 (2010-06-18)
Pregnancy complications such as pre-eclampsia and eclampsia, intrauterine growth restriction and placental abruption are thought to have a common origin related to abnormalities in the development and function of the placenta. To compare, using the best available evidence, the benefits
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica.